190 related articles for article (PubMed ID: 30733525)
1. Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types.
van de Stolpe A; Holtzer L; van Ooijen H; Inda MA; Verhaegh W
Sci Rep; 2019 Feb; 9(1):1603. PubMed ID: 30733525
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model.
van Ooijen H; Hornsveld M; Dam-de Veen C; Velter R; Dou M; Verhaegh W; Burgering B; van de Stolpe A
Am J Pathol; 2018 Sep; 188(9):1956-1972. PubMed ID: 30030980
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer.
van de Stolpe A
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30832253
[TBL] [Abstract][Full Text] [Related]
4. ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen.
Sieuwerts AM; Inda MA; Smid M; van Ooijen H; van de Stolpe A; Martens JWM; Verhaegh WFJ
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32230714
[No Abstract] [Full Text] [Related]
5. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
6. Androgen Receptor Pathway Activity Assay for Sepsis Diagnosis and Prediction of Favorable Prognosis.
Bouwman W; Verhaegh W; van de Stolpe A
Front Med (Lausanne); 2021; 8():767145. PubMed ID: 34888328
[No Abstract] [Full Text] [Related]
7. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
8. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation.
Trotta AP; Need EF; Selth LA; Chopra S; Pinnock CB; Leach DA; Coetzee GA; Butler LM; Tilley WD; Buchanan G
Int J Cancer; 2013 Dec; 133(12):2812-23. PubMed ID: 23740762
[TBL] [Abstract][Full Text] [Related]
10. Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling.
Azad AK; Lawen A; Keith JM
BMC Syst Biol; 2015 Jan; 9():2. PubMed ID: 25599599
[TBL] [Abstract][Full Text] [Related]
11. Measurement of activity of developmental signal transduction pathways to quantify stem cell pluripotency and phenotypically characterize differentiated cells.
Holtzer L; Wesseling-Rozendaal Y; Verhaegh W; van de Stolpe A
Stem Cell Res; 2022 May; 61():102748. PubMed ID: 35325817
[TBL] [Abstract][Full Text] [Related]
12. PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer.
Caromile LA; Dortche K; Rahman MM; Grant CL; Stoddard C; Ferrer FA; Shapiro LH
Sci Signal; 2017 Mar; 10(470):. PubMed ID: 28292957
[TBL] [Abstract][Full Text] [Related]
13. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. The molecular underpinnings of prostate cancer: impacts on management and pathology practice.
Rodrigues DN; Boysen G; Sumanasuriya S; Seed G; Marzo AM; de Bono J
J Pathol; 2017 Jan; 241(2):173-182. PubMed ID: 27753448
[TBL] [Abstract][Full Text] [Related]
16. Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance.
Yeh Y; Guo Q; Connelly Z; Cheng S; Yang S; Prieto-Dominguez N; Yu X
Adv Exp Med Biol; 2019; 1210():351-378. PubMed ID: 31900917
[TBL] [Abstract][Full Text] [Related]
17. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
Benitez DA; Pozo-Guisado E; Clementi M; Castellón E; Fernandez-Salguero PM
Br J Cancer; 2007 May; 96(10):1595-604. PubMed ID: 17486135
[TBL] [Abstract][Full Text] [Related]
18. RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies.
van de Stolpe A; Verhaegh W; Blay JY; Ma CX; Pauwels P; Pegram M; Prenen H; De Ruysscher D; Saba NF; Slovin SF; Willard-Gallo K; Husain H
Front Genet; 2020; 11():598118. PubMed ID: 33613616
[TBL] [Abstract][Full Text] [Related]
19. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway.
Guo S; Sonenshein GE
Mol Cell Biol; 2004 Oct; 24(19):8681-90. PubMed ID: 15367686
[TBL] [Abstract][Full Text] [Related]
20. Oleic acid promotes prostate cancer malignant phenotype via the G protein-coupled receptor FFA1/GPR40.
Liotti A; Cosimato V; Mirra P; Calì G; Conza D; Secondo A; Luongo G; Terracciano D; Formisano P; Beguinot F; Insabato L; Ulianich L
J Cell Physiol; 2018 Sep; 233(9):7367-7378. PubMed ID: 29663374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
